Browse result page of AntiTbPdb
The total number entries retrieved from this search are 650
ID | Name | Sequence | N-Terminal Modification | C-Terminal Modification | Chemical Modification | Linear/Cyclic | Length | Chirality | Nature | Source | Origin | Species | Strain | Inhibition Concentration | In vitro/ In vivo | Cell Line | Intracellular Inhibition | Cytotoxicity | Animal Model | Effective Dose in model organism | Immune Responce | Mechanism of Action | Target | Combination Therapy | Other Activities | Year of Publication | Pubmed ID/ Patent No. |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
antitb_1834 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X004244 | MIC = 16.9 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1835 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X005282 | MIC = 9.6 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1836 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X005319 | MIC = 19.2 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1837 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X001354 | MIC = 9.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1838 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X003899 | MIC = 22.9 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1839 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to streptomycin (rSM, ATCC 35820) | MIC = 11.6 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1840 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to rifampin (rRMP, ATCC 35838) | MIC = 9.6 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1841 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to kanamycin (rKM, ATCC 35827) | MIC = 12.4 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1842 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to isoniazid (rINH, ATCC 35822) | MIC = 12.1 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1843 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to cycloserine (rCS, ATCC 35826) | MIC = 20.6 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1844 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to moxifloxacin (rMOX) | MIC = 9.0 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1845 | Hytramycin V | (METH-Ala)-(D-Pip)-L-(D-VAL)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to capreomycin (rCAP) | MIC = 12.1 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1846 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv | MIC = 6.0 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1847 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X004439 | MIC = 4.4 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1848 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X004244 | MIC = 4.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1849 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X005282 | MIC = 4.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1850 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X005319 | MIC = 4.8 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1851 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X001354 | MIC = 4.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1852 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Clinical isolate, X003899 | MIC = 4.8 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1853 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to streptomycin (rSM, ATCC 35820) | MIC = 4.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1854 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to rifampin (rRMP, ATCC 35838) | MIC = 4.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1855 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to kanamycin (rKM, ATCC 35827) | MIC = 4.9 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1856 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to isoniazid (rINH, ATCC 35822) | MIC = 4.7 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1857 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to cycloserine (rCS, ATCC 35826) | MIC = 7.4 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1858 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to moxifloxacin (rMOX) | MIC = 4.0 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1859 | Hytramycin I | (METH-Ala)-(D-Pip)-L-( D-Allo-ILE)-Pip-(D-Pip) | Free | Free | METH-ALA= Methylated alanine, D-Pip = piperazic acid moieties, D-Allo-ILE= D form of Allo-isoleucine | Cyclic (Intrachain bond between 1-6) | 6 | Mix | NA | Natural | From Streptomyces hygroscopicus strain ECUM 14046 | Mycobacterium tuberculosis | Mycobacterium tuberculosis resistant to capreomycin (rCAP) | MIC = 4.8 μg/mL | In vitro | None | NA | NA | NA | NA | NA | NA | NA | NA | Antibacterial (Escherichia coli (ATCC 25922), Staphylococcus aureus (ATCC 29213), Acinetobacter baumannii (ATCC BAA-747), Enterococcus faecalis (ATCC 29212), and Pseudomonas aeruginosa (ATCC 27853) | 2013 | 24224794 |
antitb_1869 | Mastoparan Polybia-MPII | INWLKLGKMVIDAL | Free | Free | None | Linear | 14 | L | Cationic | Natural | Isolated from venom of the social wasp Pseudopolybia vespiceps testacea | Mycobacterium abscessus | Mycobacterium abscessus subsp. massiliense GO06 | 80% inhibition at 12.5 μM | In vitro | murine macrophages, human and mouse erythrocytes | 80% inhibition at 12.5 μM | 50% hemolysis at 24.18 μM and 48.47 μM against mouse and human erythrocytes respectively | NA | NA | NA | membrane pore formation | cell membrane | NA | Antifungal (Candida albicans and Cryptococcus neoformans) and Antibacterial (Staphylococcus aureus) | 2017 | 28108242 |
antitb_1870 | Tat(47–57) | YGRKKRRQRRR | Free | Free | None | Linear | 11 | L | Cationic | Protein Derived | HIV transactivator protein | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1871 | Penetratin | RQIKIWFQNRRMKWKK | Free | Free | None | Linear | 16 | L | Cationic | Protein Derived | Drosophila Antennapedia protein | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1872 | Transportan | AGYLLGKINLKALAALAKKIL | Free | Free | None | Linear | 21 | L | Cationic | Synthetic | Constructed from Galanin and Mastoparan proteins | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC = 80 μM | In vitro | RBC | NA | 50% hemolysis at 38.0 ± 3.79 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1873 | Magainin | GIGKFLHSAKKFGKAFVGEIMNS | Free | Free | None | Linear | 23 | L | Cationic | Natural | Peptide from Xenopus laevis skin | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1874 | Buforin II (5–21) | RAGLQFPVGRVHRLLRK | Free | Free | None | Linear | 17 | L | Cationic | Natural | Peptide from the stomach tissue of Bufo bufo garagrizans | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1875 | GranF2 | VCRTGRSRWRDVCRNFMRRYQSR | Free | Free | None | Linear | 23 | L | Cationic | Protein Derived | Peptide derived from Granulysin protein | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1876 | Dhvar4 | KRLFKKLLFSLRKY | Free | Free | None | Linear | 14 | L | Cationic | Protein Derived | Human salivary Histatin derivative | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1877 | Crot(1–9,38–42) | YKQCHKKGGKKGSG | Free | Free | None | Linear | 14 | L | Cationic | Natural | Crotamine, a toxin of Crotalus durissus terrificus | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1878 | CM15 | KWKLFKKIGAVLKVL | Free | Free | None | Linear | 15 | L | Cationic | Synthetic | From Cecropin A and Melittin sequences | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at 18.9 ± 1.71 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1879 | Melittin | GIGAVLKVLTTGLPALISWIKRKRQQ | Free | Free | None | Linear | 26 | L | Cationic | Natural | Venom of Apis mellifera | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at 0.339 ± 0.0854 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1880 | OT20 | TKPKGTKPKGTKPKGTKPKG | Free | Free | None | Linear | 20 | L | Cationic | Synthetic | Tetramer derivative of tuftsin sequence | Mycobacterium tuberculosis | Mycobacterium tuberculosis H37Rv (ATCC 27294) | MIC >300 μM | In vitro | RBC | NA | 50% hemolysis at >300 μM | NA | NA | NA | NA | NA | NA | Antibacterial (Streptococcus pneumoniae) | 2017 | 28314993 |
antitb_1881 | Polydim-I | AVAGEKLWLLPHLLKMLLTPTP | Free | Free | None | Linear | 22 | L | Amphipathic | Natural | Isolated from the venom of the Neotropical wasp Polybia dimorpha | Mycobacterium abscessus | Mycobacterium abscessus subsp. massiliense isolates GO 01, GO 06, GO 07, GO 08, GO 13, and GO 18, CRM0020 (Mycobacterium abscessus subsp. massiliense), and ATCC19977 (Mycobacterium abscessus subsp. abscessus) | MIC = 60.8 μg/mL | Both | Peritoneal macrophages, J774 macrophages cells, human red blood cells | Treatment of infected macrophages with 7.6 μg/mL of Polydim-I decreased approximately 50% of the bacterial load | Non-cytotoxic, 10% cytotoxicity on J774 cells at concentrations above 121.6 μg/mL (10%) and concentrations up to 121.6 μg/mL presented less than 2.5% of hemolytic activity | 6 to 8 weeks old BALB/c and IFN-γKO (Knockout) female mice | 2 mg/kg/mLW shows 90% reduction in bacterial load | NA | Cell wall disruption | Cell wall | None | NA | 2016 | 26930596 |
antitb_1882 | Propeptin-2 | GYPWWDYRDLFGGHTFI | Involved in Cyclic bond formation between amino acid 1 and 9 | Free | None | Cyclic | 17 | D | NA | Natural | Isolated from Microbispora species SNA-115 | Mycobacterium phlei | Mycobacterium phlei IFO 3158 | 40 μg/disc | In vitro | NA | Treatment of infected Mycobacterium phlei with 40 μg/disc of Propeptin-2 decreased approximately 90% of the bacterial load in zone inhibition assay | NA | NA | NA | NA | NA | NA | None | Antibacterial against silkworm | 2007 | 17827663 |
antitb_1883 | Propeptin | GYPWWDYRDLFGGHTFISP | Involved in Cyclic bond formation between amino acid 1 and 9 | Free | None | Cyclic | 19 | D | NA | Natural | Isolated from Microbispora species SNA-115 | Mycobacterium smegmatis | Mycobacterium smegmatis M341 | MIC90 = 100 μg/mL | In vivo | NA | Treatment of infected Mycobacterium smegmatis with 100 μg/ml of Propeptin decreased approximately 90% of the bacterial load | NA | Silkworm hemolymph infected with mycobacterium smegmatis at (1.25 × 107 CFU) | 1.25 × 107 CFU | NA | NA | NA | None | None | 2017 | 28446822 |
antitb_1893 | Human lactoferricin 1-11 | GRRRRSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2447 smT | IC50 = 15.8 ± 4.5 μM | In vitro | NA | Tratment with this concentration inhibit 50% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1894 | Human lactoferricin 1-11 | GRRRRSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2447 smT | IC90 = 34.6 ± 22.4 μM | In vitro | NA | Tratment with this concentration inhibit 90% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1895 | Human lactoferricin 1-11 | GRRRRSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2-151 smT | IC50 = 11.0 ± 4.1 μM | In vitro | NA | Tratment with this concentration inhibit 50% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1896 | Human lactoferricin 1-11 | GRRRRSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2-151 smT | IC90 = 65.8 ± 19.13 μM | In vitro | NA | Tratment with this concentration inhibit 90% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1897 | Human lactoferricin 1-11 | GRRRRSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2-151 smD | IC50 = 15.2± 2.9 μM | In vitro | NA | Tratment with this concentration inhibit 50% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1898 | Human lactoferricin 1-11 | GRRRRSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2-151 smD | IC90 = 37.9 ± 15.9 μM | In vitro | NA | Tratment with this concentration inhibit 90% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1899 | Human lactoferricin 1-11 | GKKKKSVQWCA | Free | Free | None | Linear | 11 | L | Cationic | Natural | Derived from human lactoferricin protein | Mycobacterium avium | Mycobacterium avium | Mycobacterium avium 2447 smT | In vitro | NA | Tratment with this concentration inhibit 50% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1900 | Bovine lactoferricin 17-30 | FKCRRWQWRMKKLG | Free | Free | None | Linear | 14 | L | Cationic | Natural | Derived from bovine lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2447 smT | IC50 = 14.2 ± 1.5 μM | In vitro | NA | Tratment with this concentration inhibit 50% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |
antitb_1901 | Bovine lactoferricin 17-30 | FKCRRWQWRMKKLG | Free | Free | None | Linear | 14 | L | Cationic | Natural | Derived from bovine lactoferricin protein | Mycobacterium avium | Mycobacterium avium 2447 smT | IC90 = 18.9 ± 4.0 μM | In vitro | NA | Tratment with this concentration inhibit 90% bacterial growth | NA | NA | NA | NA | NA | Lipid bilayer | NA | NA | 2014 | 24709266 |